Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

达比加群酯胶囊 - NMPA Drug Approval Details

Approvals/NMPA/Dabigatran Etexilate Capsules

Approved

化学药品

Dabigatran Etexilate Capsules

Unknown🇨🇳 National Medical Products Administration

Approval Date: Jan 14, 2026
Approval ID: 8mdl7iVEQdb
Company: Unknown
Type: 化学药品

Approval Details

Approval Id: 8mdl7iVEQdb
Approval Number: 国药准字HJ20260009
Generic Name: 达比加群酯胶囊
Generic Name En: Dabigatran Etexilate Capsules
Drug Type: 化学药品
Dosage Form: 胶囊剂
Strength: 150mg（按C₃₄H₄₁N₇O₅计）
Reg Date: 2026-01-14
Expired Date: 2031-01-13

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jan 14, 2026

Approval ID

8mdl7iVEQdb

Type

化学药品

Back to NMPA Approvals